アフターアワーズ： 1.48

Unity Biotechnology Inc (UBX)

Unity Biotechnology Inc (UBX) 最新ニュース

Unity Biotechnology Inc (UBX)

Unity Biotechnology Inc (UBX) 最新ニュース

Unity Biotechnology (NASDAQ:UBX) Rating Reiterated by HC Wainwright - Defense World

Unity Biotechnology, Inc. (NASDAQ:UBX) to Post Q2 2024 Earnings of ($0.44) Per Share, HC Wainwright Forecasts - Defense World

All You Need to Know About UNITY Biotechnology (UBX) Rating Upgrade to Buy - Yahoo Finance

Unity Biotechnology reports Q1 EPS (34c), consensus (48c) - TipRanks.com - TipRanks

UNITY Biotechnology, Inc. Reports First Quarter 2024 Financial Results and Business Updates - GlobeNewswire

Unity Biotechnology's Shares March Higher, Can It Continue? - Yahoo Movies UK

Do Directors Own Unity Biotechnology, Inc. (NASDAQ:UBX) Shares? - Yahoo Lifestyle UK

UNITY Biotechnology Announces Upcoming Presentations at the ARVO 2024 Annual Meeting - Yahoo

Unity Biotechnology announces extension of Phase 2b ASPIRE study of UBX1325 - TipRanks.com - TipRanks

UNITY Biotechnology Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DME - GlobeNewswire

UNITY Biotechnology Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DME - GlobeNewswire

Visa To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday

Unity Biotech stock PT cut by H.C. Wainwright on ASPIRE trial update - Investing.com

UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

Here's Why We're A Bit Worried About Unity Biotechnology's (NASDAQ:UBX) Cash Burn Situation - Simply Wall St

New research supports therapeutic potential of senolytics in DME - Longevity.Technology

New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-lasting, Disease ... - Yahoo Finance

Unity doses first subjects in Phase II DME therapy trial - Clinical Trials Arena

Companies Like Unity Biotechnology (NASDAQ:UBX) Could Be Quite Risky - Yahoo Finance

UNITY Biotechnology Announces Exercise of Warrants for $4.38 Million in Gross Proceeds - Yahoo Finance

Inside Bryan Johnson and other Silicon Valley billionaires’ pursuit of immortality - Longevity.Technology

Are Longevity Stocks the Next Trillion-Dollar Industry? 3 Anti-Aging Picks - InvestorPlace

Jeff Bezos, Mark Zuckerberg And Sam Altman Among The Billionaires Investing In Anti-Aging Technology. Who Else ... - Yahoo Finance

UNITY Biotechnology Announces 48-Week Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet ... - GlobeNewswire

Unity Biotechnology Inc CEO Anirvan Ghosh Sells 1,246 Shares - Yahoo Finance

Age-Related Macular Degeneration Market to Grow Rapidly by 2032, Predicts DelveInsight | Key Companies - Opthea ... - GlobeNewswire

UNITY Announces Design of Phase 2b ASPIRE Study Evaluating UBX1325 in Diabetic Macular Edema (DME) - Yahoo Finance

'Self-harm and decay are not inevitable': This 45-year-old tech mogul spends $2M per year to get an '18-year-old body ... - Yahoo Finance

UNITY Biotech announces positive results from Phase 2 BEHOLD study on diabetic macular edema - Longevity.Technology

Unity preps for Eylea battle following extended midstage test - Fierce Biotech

Why Is Unity Biotechnology (UBX) Stock Down 52% Today? - InvestorPlace

Unity Biotechnology: One Last Chance With UBX1325 (NASDAQ:UBX) - Seeking Alpha

Senolytic Therapies Pose Revolutionary Potential to Roll Back Diseases of Aging - BioSpace

UNITY Biotechnology Announces Positive 24-Week Data from Phase 2 BEHOLD Study of UBX1325 in Patients with ... - GlobeNewswire

Unity Biotechnology (UBX): Share Consolidation On The Back Of Positive Trial Results - Seeking Alpha

UNITY Biotechnology Announces Reverse Stock Split Effective at 5:00 PM Eastern Time Today - GlobeNewswire

The Three Best Anti-Aging Stocks to Buy in September - Yahoo Finance

UNITY cuts lead program after clinical trial fail - Longevity.Technology

Campisi Lab to partner with pharma firm on senescence - Longevity.Technology

UNITY Biotech doubles share price after positive data for diabetes-related vision loss drug - Longevity.Technology

Latham & Watkins Advises UNITY Biotechnology in Its Upsized Public Offering - Latham & Watkins LLP -

UNITY Biotechnology Announces Positive Data in Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic ... - GlobeNewswire

As billionaires race to fund anti-aging projects, a much-discussed trial goes overlooked - STAT

Rebuilt Amish market nearly complete after fire in Unity - WGME

Unity once again lays off large number of staff, narrows focus to ophthalmology assets - Fierce Biotech

Unity's Amish Community Market destroyed in fire - WGME

Jeff Bezos has reportedly invested in anti-aging startup Altos Labs - New York Post

Ascentage Pharma Announces Another Milestone Payment from Its Licensee UNITY Biotechnology, Rapidly ... - PR Newswire

A Look At Unity's UBX1325 Phase 1 Results (NASDAQ:UBX) - Seeking Alpha

UNITY's drug shows benefit in advanced vascular eye disease - Clinical Trials Arena

UBXに似た銘柄